BioCryst Pharma’s BCX9930 Fast Track’d for red blood cell disease

The FDA has granted Fast Track designation for BioCryst Pharmaceuticals’ (NASDAQ:BCRX) oral Factor D inhibitor, BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.

https://seekingalpha.com/news/3598838-biocryst-pharmas-bcx9930-fast-trackd-for-red-blood-cell-disease